Brief: Valneva Continues To See Positive Risk-Benefit In Majority Of People With Potential Exposure To Disease
07/05/2025 17:32
May 7 (Reuters) - Valneva SE VLS.PA: VALNEVA PROVIDES UPDATE FOLLOWING EUROPEAN MEDICINES AGENCY ANNOUNCEMENT ON USE OF IXCHIQ® IN ELDERLY VALNEVA SE: TO CONTINUE TO MONITOR ALL REPORTED SERIOUS ADVERSE EVENTS AND FULLY COOPERATE WITH HEALTH AUTHORITIES VALNEVA SE: CONTINUES TO SEE A POSITIVE RISK-BENEFIT IN VAST MAJORITY OF PEOPLE WITH POTENTIAL EXPOSURE TO DISEASE Source text: ID:nGNX6MSbVq Further company coverage: VLS.PA (((( Reuters.Briefs@thomsonreuters.com ;));))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency